Related Experiment Video
Updated: Jun 22, 2026
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Episodic Src activation in uveal melanoma revealed by kinase activity profiling
W Maat1, M el Filali, A Dirks-Mulder
1Department of Ophthalmology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
British Journal of Cancer
|July 2, 2009
Summary
Src kinase is crucial for uveal melanoma (UM) growth, but metastatic UM may resist Src inhibition. Targeting Src shows promise for primary UM treatment, necessitating alternative strategies for metastatic disease.
Area of Science:
- Oncology
- Molecular Biology
- Melanoma Research
Background:
- The RAS/RAF/MEK/ERK pathway regulates melanocyte proliferation and differentiation.
- This pathway is constitutively activated in cutaneous and uveal melanoma (UM), promoting tumor growth.
- Unlike cutaneous melanoma, UM typically lacks BRAF and NRAS mutations.
Purpose of the Study:
- To investigate the RAS/RAF/MEK/ERK pathway in uveal melanoma.
- To identify key kinases involved in UM pathogenesis and potential therapeutic targets.
Main Methods:
- Utilized mitogen-activated protein kinase profiling.
- Employed tyrosine kinase arrays to analyze signaling pathways.
Main Results:
- Identified Src as a kinase associated with ERK1/2 activation in UM.
- Src inhibition reduced primary UM cell growth but had minimal effect on metastatic cell lines.
- Metastatic UM cell lines showed lower Src levels and reduced ERK1/2 activation, suggesting pathway independence.
Conclusions:
- Src is a significant kinase and a potential therapeutic target for primary UM.
- Metastatic UM cell lines exhibit resistance to Src inhibition.
- Alternative treatment approaches are likely necessary for managing metastatic UM.
Related Concept Videos
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...